Core Insights - PetMed Express, Inc. has filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025, with the SEC, marking a significant step in resuming normal operations and reporting [1][3] Financial Highlights - The company reported net sales of $227.0 million for fiscal 2025, which is below the preliminary estimated range of $231.6 million to $233.6 million, primarily due to the restatement of promotional sales reimbursements from revenues to cost of sales [6] - PetMed Express experienced a net loss of $6.3 million, exceeding the previously announced preliminary estimated range of $4.5 million to $5.0 million, largely due to a $1.2 million non-cash impairment charge for intangible assets [6] - As of March 31, 2025, the company had cash reserves of $54.7 million and no debt [6] Company Overview - Founded in 1996, PetMed Express is a pioneer in the direct-to-consumer pet healthcare sector, operating as a trusted national online pharmacy licensed across all 50 states [4] - The company offers a comprehensive range of pet health solutions, including top-brand and generic pharmaceuticals, compounded medications, and over-the-counter supplements and nutrition [4] - PetMed Express aims to empower pet parents to help their pets live longer, healthier lives through value, convenience, and care [4]